Dermata Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
DRMA$0.71-7.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| For the year endedDecember 31, | ||||
|---|---|---|---|---|
| 2024 · 2023 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(12,287,461) | $(7,794,690) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 657,649 | 522,082 | ||
| Increase (decrease) in cash resulting from changes in: | ||||
| Prepaid expenses and other current assets | 168,181 | 162,695 | ||
| Accounts payable | (108,512) | 369,326 | ||
| Accrued and other current liabilities | 407,195 | 331,656 | ||
| Total adjustments to reconcile net loss to cash used in operations | 1,124,513 | 1,385,759 | ||
| Net cash used in operating activities | (11,162,948) | (6,408,931) | ||
| Cash flows from financing activities: | ||||
| Proceeds from issuance of Common Stock, pre-funded warrants, and warrants, net of issuance costs | 6,886,102 | 7,605,625 | ||
| Proceeds from exercise of pre-funded warrants | 1,109 | 187 | ||
| Payment for fractional shares in reverse stock split | (828) | (40) | ||
| Net cash provided by financing activities | 6,886,383 | 7,605,772 | ||
| Net increase (decrease) in cash and cash equivalents | (4,276,565) | 1,196,841 | ||
| Cash and cash equivalents at beginning of period | 7,438,135 | 6,241,294 | ||
| Cash and cash equivalents at end of period | $3,161,570 | $7,438,135 | ||
| Supplemental disclosure: | ||||
| Cash paid for taxes | $950 | $950 | ||
| Non-cash financing activities: | ||||
| Incremental fair value of March 2023 warrant modification | $ | - | $144,765 | |
| Incremental fair value of November 2023 warrant inducement | $ | - | $2,995,343 | |
| Issuance of abeyance shares | $18 | $ | - | |
| Incremental fair value of May 2024 warrant inducement | $1,526,232 | $ | - | |
| Issuance costs in accounts payable | $50,495 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.